Spironolactone in Patients With Single Ventricle Heart

Not Applicable

Completed

Conditions: Congenital Disorders

Interventions: Drug: Spironolactone (drug)

Registration Number: NCT00211081

Lead Sponsor: Emory University

Brief Summary: Ultrasound is a technique that can provide images of the blood vessels such as arteries. The size of the arteries, such as the main blood vessel in the arm, can change under different conditions. Using ultrasound we can see how arteries change with movement or even drugs. We want to use ultrasound to see how blood vessels look in patients with Congestive Heart Failure (CHF) and to also see how a drug called Spironolactone, commonly prescribed for patients with this disease, effects blood vessel function in patients with congestive heart failure. This information may be used to change the standard of care for patients with heart failure especially if we show that Spironolactone has a positive effect on vessel function in patients with CHF.

Detailed Description: Spironolactone The starting dose of spironolactone is 1 mg/kg/day. After two weeks this dose will be doubled to the same maximum dose (2/mg/kg/day) as in RALES. If side effects occur or plasma urea and electrolytes became deranged the dose will be halved. Patients unable to tolerate the minimum dose will be withdrawn. Measurement of serum electrolytes will occur at baseline, at two weeks, and at time of repeat evaluation.

Endothelial Function

Subjects with single ventricle will have an evaluation of endothelial function:

1. At baseline

2. On spironolactone- 4-5 weeks after initial study.

Imaging protocol:

The diameter of the brachial artery will be measured from two-dimensional ultrasound images, using a 12 MHz linear array transducer and an Accuson Sequoia system (Accuson, Mountainview, California). Measurements of the brachial artery will be obtained:

1. In a resting state

2. During limb ischemia

3. In response to reactive hyperemia

4. At rest

Reactive hyperemia will be induced by inflating a standard blood pressure cuff to 50 mm Hg above the systolic blood pressure for 4.5 minutes and then deflating the cuff.

After data collection, the DICOM-formatted images will be transferred to a PC for investigator-blinded measurement of brachial artery diameter using image analysis software (Brachial Tools 3.1, Medical Imaging Applications, Iowa).

Measurement of prognostic markers:

Blood samples

Plasma beta-type natriuretic peptide, form assay, TNF alpha and a Cytokine panel will be drawn at base line and at the final 4-5 week visit for this study.

Samples will be collected between 11 am and 1 pm after 30 minutes' supine rest. The samples will be centrifuged and plasma stored at -70°C (peptides) or -20°C (other samples). Plasma \[beta\]-type natriuretic peptide (BNP) samples will be collected into EDTA and aprotonin and measured by radioimmunoassay 6-minute walk test.

A 6-minute walk test will be performed at the first visit and the last visit. During this test, signs and symptoms will be recorded (i.e. chest pain and shortness of breath) to determine toleration of daily activity. A doctor or nurse will conduct this test and the patient will be provided the opportunity to stop or rest if symptoms become severe.

Outcome measures

The primary outcome measure will be the change in flow mediated dilation (during reactive hyperemia). This will be expressed as a percentage.

Secondary outcome measures will include changes in BNP, Form assay, TNF alpha, Cytokine panels and the 6-minute walk test.

Statistical analysis

We and others have previously shown that asymptomatic patients with the Fontan operation have a mean flow-mediated dilation of approximately 4% compared to 8-9% in controls. In order to detect a 25% change in FMD, with a power of 0.80, the current study would require a patient population of 13 cases. There are currently over 40 patients with single ventricle who are followed in the adult congenital clinic at Emory University.

We plan on enrolling 20 patients into this study.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 12

Inclusion Criteria

Single Ventricle Subjects
>17 years
have undergone Fontan Procedure

Exclusion Criteria

History of smoking
Diabetes mellitus
Renal failure (serum creatinine > 2.5 mg/dl)
Recovering spironolactone for maintenance therapy
History of hyperkalemia (serum potassium> 5.5 mEq/L)

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Open Label	Spironolactone (drug)	-

Primary Outcome Measures

Name	Time	Method
Change in Flow Mediated Dilation	Baseline, Post-Intervention (4 Weeks)	Flow-mediated dilation of the brachial artery will be measured using high-resolution ultrasound. Arterial diameter will be measured above the small cavity in the elbow joint from ultrasound images at rest in response to an increase in blood flow to the area.

Secondary Outcome Measures

Name	Time	Method
C-Reactive Protein Level	Baseline, Post-Intervention (4 Weeks)	The normal reference range for C-reactive protein is as follows: CRP: 0-10mg/L
Interleukin-6 (IL-6) Level	Baseline, Post-Intervention (4 Weeks)	The normal result for IL-6 for Interleukin 6 is \< 5pg/ml.
Interleukin 1 Beta (IL1b) Level	Baseline, Post-Intervention (4 Weeks)	The normal result for IL1b is \<3.9 pg/mL.
Interleukin-10 (IL10) Level	Baseline, Post-Intervention (4 Weeks)	The normal result for IL-10 for Interleukin 10 is \< 18pg/ml.
Tumor Necrosis Factor-Alpha (TNF-a) Level	Baseline, Post-Intervention (4 Weeks)	The normal result for TNF-a is \<5.6 pg/mL.
Change in 6 Minute Walk Test Score	Baseline, Post-Intervention (4 Weeks)